Dr. Hui Zhang 张辉
Chief Physician
Department of Hepatobiliary and Pancreatic Oncology Surgery, Fujian Cancer Hospital, Fuzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgery-based comprehensive treatment for colorectal cancer liver metastases and primary liver cancer.
Dr. Zhang graduated from Fudan University in 2004 and trained at Peking University Cancer Hospital and Fudan University Zhongshan Hospital in gastrointestinal surgical oncology. Dr. Zhang serves as secretary for the multidisciplinary team on primary and metastatic liver cancer. Research includes one provincial natural science fund project and participation in four national and provincial projects. Dr. Zhang has published over 10 papers, including 4 SCI articles.
Professional roles
- Member, Liver Cancer Professional Committee, China Anti-Cancer Association
- Youth Member, Liver Cancer Professional Committee, Chinese Medical Doctor Association
- Leader, Liver Metastasis Group, Colorectal Cancer Professional Committee, Fujian Anti-Cancer Association
- Member and Secretary, Tumor Metastasis Professional Committee, Fujian Anti-Cancer Association
Name order: in Chinese the family name comes first (Zhang Hui). Papers usually list the name as Hui Zhang or Zhang H.
Selected publications
33 papers on PubMed matched by name and affiliation; 8 as first or senior author since 2016. Most recent first- or senior-author papers:
- Front Oncol, 2026 (senior author): Correction: Experience sharing of endoscopy-assisted total mastectomy with and without immediate breast reconstruction. PubMed 41695323
- Front Oncol, 2025 (senior author): Experience sharing of endoscopy-assisted total mastectomy with and without immediate breast reconstruction. PubMed 41267987
- Front Oncol, 2025 (senior author): Clinical study of (99m)Tc-Rituximab combined with dyes double tracing for axillary sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer. PubMed 40842577
- Ann Surg Oncol, 2025 (first author): ASO Author Reflections: Why are the Identification and Verification of Key Genes in Colorectal Cancer Liver Metastases so Important?. PubMed 39489828
- Ann Surg Oncol, 2024 (first author): Identification and Verification of Key Genes in Colorectal Cancer Liver Metastases Through Analysis of Single-Cell Sequencing Data and TCGA Data. PubMed 39382748
- Mol Carcinog, 2023 (first author): Activin A/ACVR2A axis inhibits epithelial-to-mesenchymal transition in colon cancer by activating SMAD2. PubMed 37378449
- Med Sci Monit, 2020 (first author): Small Nucleolar RNA Host Gene 1 (SNHG1) and Chromosome 2 Open Reading Frame 48 (C2orf48) as Potential Prognostic Signatures for Liver Cancer by Constructing Regulatory Networks. PubMed 32036380
- Oncol Lett, 2019 (first author): Association between the expression of carbonic anhydrase II and clinicopathological features of hepatocellular carcinoma. PubMed 31186798
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion